|
Seizures
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases.
|
31820119 |
2020 |
|
Feeding difficulties
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases.
|
31820119 |
2020 |
|
Global developmental delay
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases.
|
31820119 |
2020 |
|
Intellectual Disability
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases.
|
31820119 |
2020 |
|
Abnormality of vision
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases.
|
31820119 |
2020 |
|
Abnormality of the face
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases.
|
31820119 |
2020 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The isoform switch of metabolism-related gene UGP2 (UDP-glucose pyrophosphorylase 2) might play an essential role in HCC.
|
30014619 |
2019 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Correction: LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma.
|
30131857 |
2018 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma.
|
29228655 |
2017 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Subsequent TMA analysis revealed a three marker panel of HSP70, ASS1, and UGP2 to be statistically significant in stratifying the two groups of HCC patients.
|
24946162 |
2014 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
A loss-of-function study showed that knockdown of UGP2 decreases U251 cell growth, migration, and invasion in vivo and vitro.
|
30816613 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of lncRNA-SVUGP2 depressed proliferation, induced apoptosis, and suppressed migration and invasion of A549 and H1975 cells.
|
31401873 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Moreover, lncRNA-SVUGP2 suppresses the invasion ability of liver cancer cell lines and downregulates the mRNA and protein levels of MMP2 and 9.
|
29228655 |
2017 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Positive UGP2 and CFL1 expression in cases with high differentiation, no lymph node metastasis, no surrounding invasion, and TNM (tumor-node-metastasis) staging I or/and II were significantly lower than those in cases with poor differentiation, lymph node metastasis, surrounding invasion, and TNM stage III and/or IV.
|
29347944 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Overexpression of lncRNA-SVUGP2 in HepG2 and Hep3B liver cancer cells suppresses cell proliferation <i>in vitro</i> and tumor growth <i>in vivo</i>.
|
29228655 |
2017 |
|
Encephalopathies
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Our study identifies a recurrent start codon mutation in UGP2 as a cause of a novel autosomal recessive DEE syndrome.
|
31820119 |
2020 |
|
Epileptic encephalopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases.
|
31820119 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our data reveal that lncRNA-SVUGP2 is under-expressed in NSCLC cells and the reduced expression of lncRNA-SVUGP2 may enhance the development and process of NSCLC by interacting with EZH2 and activating Wnt/β-catenin pathway.
|
31401873 |
2019 |
|
Glioblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Based on the random survival forest model, we identified UDP-glucose pyrophosphorylase 2 (UGP2) (upregulated gene) had a significant effect on GBM prognosis.
|
30816613 |
2019 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, UGP2 expression is aberrantly overexpressed in human glioma and positively correlated with pathologic grade.
|
30816613 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Based on the random survival forest model, we identified UDP-glucose pyrophosphorylase 2 (UGP2) (upregulated gene) had a significant effect on GBM prognosis.
|
30816613 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Positive expression of UGP2 and CFL1 can serve a valuable prognostic factor in pancreatic cancer.
|
29347944 |
2018 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Positive expression of UGP2 and CFL1 can serve a valuable prognostic factor in pancreatic cancer.
|
29347944 |
2018 |
|
Carcinoma, Pancreatic Ductal
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study investigated UGP2 (uridine diphosphate-glucose pyrophosphorylase-2) and CFL1 (cofilin-1) expression in pancreatic ductal carcinoma (PDC), paracancerous tissue (PT), benign lesions (BL), and normal tissue (NT) and their clinicopathological significance.
|
29347944 |
2018 |
|
Paroxysmal Nonkinesigenic Dyskinesia 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
UGP2 and CFL1 expression in PDC were positively correlated.
|
29347944 |
2018 |